Search

Your search keyword '"Yan, Haijiao"' showing total 23 results
Start Over Author "Yan, Haijiao"
23 results on '"Yan, Haijiao"'

6. Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies

Author

Huang, Hui-qiang, primary, Li, Zengjun, additional, Cheng, Gang, additional, Yan, Gao, additional, Yao, Zhihua, additional, Zhang, Guifang, additional, Wang, Xiaoguang, additional, Han, Zhengxiang, additional, Chen, Yong, additional, Yan, Haijiao, additional, Zheng, Weie, additional, Yan, Jun, additional, Gu, Yulan, additional, Ren, Zhangxia, additional, Zhao, Rusen, additional, Zhang, Ningling, additional, and Ma, Jun, additional

Published
2021
Full Text
View/download PDF

8. Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies in a real-world setting.

Author

Ma, Jun, primary, Huang, Huiqiang, additional, Fu, Peifen, additional, Xu, Nong, additional, Mao, Chenyu, additional, Cheng, Gang, additional, Yan, Haijiao, additional, Li, Yongqing, additional, Shi, Yanxia, additional, Wang, Yongsheng, additional, Yao, Yumin, additional, Chen, Liang, additional, Chen, Yong, additional, Zhang, Ningling, additional, Zhang, Guifang, additional, Ren, Zhangxia, additional, Li, Zengjun, additional, Song, Lihua, additional, and Qin, Shukui, additional

Published
2021
Full Text
View/download PDF

9. Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study

Author

Ma, Jun, primary, Huang, Huiqiang, additional, Fu, Peifen, additional, Xu, Nong, additional, Mao, Chenyu, additional, Cheng, Gang, additional, Yan, Haijiao, additional, Li, Yongqing, additional, Shi, Yanxia, additional, Wang, Yongsheng, additional, Yao, Yumin, additional, Chen, Liang, additional, Chen, Yong, additional, Zhang, Ningling, additional, Zhang, Guifang, additional, Ren, Zhangxia, additional, Li, Zengjun, additional, Song, Lihua, additional, Xu, Ruihua, additional, and Qin, Shukui, additional

Published
2021
Full Text
View/download PDF

14. The Prognostic Value of the Prognostic Nutritional Index (PNI) in Radically Resected Esophagogastric Junction Adenocarcinoma.

Author

Ge, Kele, Fang, Cheng, Zhu, Danxia, Yan, Haijiao, Wang, Qi, Chen, Wenyu, and Wu, Jun

Subjects
ADENOCARCINOMA, KRUSKAL-Wallis Test, INFLAMMATION, MULTIVARIATE analysis, POSTOPERATIVE care, SURVIVAL analysis (Biometry), CHI-squared test, DESCRIPTIVE statistics, BODY mass index, ESOPHAGEAL tumors, NUTRITIONAL status
Abstract

To determine the influence of preoperative prognostic nutritional index in adenocarcinoma of the esophagogastric junction, this study was conducted to analyze 420 patients with adenocarcinoma of the esophagogastric junction who underwent surgery. A total of 120 healthy volunteers were included as the healthy control group. The cutoff values of prognostic nutritional index for predicting survival were obtained according to the receiver operating characteristic curve. The clinic-pathological feature and survival were compared between low and high prognostic nutritional index group. Results showed that the prognostic nutritional index in the patient group was lower than that in the healthy control group (P < 0.05). The level of prognostic nutritional index was significantly associated with tumor differentiation, Siewert type, tumor size, body mass index, and hemoglobin levels (P < 0.05). The level of prognostic nutritional index was negatively correlated with age of onset, tumor differentiation, Siewert type, tumor size, depth of tumor, but positively associated with the levels of body mass index and hemoglobin. Multivariate analysis revealed that prognostic nutritional index was an independent factor associated with disease-free survival (P = 0.027) and overall survival (P = 0.003). In conclusion, low prognostic nutritional index may be considered as an independent adverse prognostic marker in patients with adenocarcinoma of the esophagogastric junction. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

17. Association of dynamic changes of methylated SFRP2 in ctDNA with prognosis in advanced gastric cancer

Author

Xizheng Mao, Xiaodong Li, Wensong Liu, Kele Ge, Jun Wu, Yan Haijiao, Mingzhe Xiao, and Wenyu Chen

Subjects
Cancer Research, chemistry.chemical_compound, Oncology, chemistry, Tumor suppressor gene, business.industry, Cancer research, Medicine, Meth, Methylation, Cancer development, Advanced gastric cancer, business
Abstract

e15051 Background: Secreted frizzled-related protein 2 (SFRP2) is a tumor suppressor gene and its hyper methylation could cause its inactivation and promote cancer development. However, whether methylated SFRP2 (mSFRP2) in ctDNA could serve as prognostic biomarker for patients with gastric cancer has not been thoroughly studied. Methods: Stage III or IV gastric cancer patients treated with systemic chemotherapy in the Third Affiliated Hospital of Soochow University from 2015 to 2017 were included. The mSFRP2 before and during chemotherapy were dynamically detected from ctDNA by digital polymerase chain reaction-based technologies. Results: In total, 121 patients were enrolled, with 63 in stage III and 58 in stage IV. Baseline median mSFRP2 was higher in stage IV than stage III (64 VS 18 copies/ng, P < 0.001). In stage III GC, the top 50% mSFRP2 population had shorter median disease-free survival (DFS, 11.0 months VS NR; HR, 13.05; 95% CI, 3.05-55.95;) and overall survival (OS, 17.0 months VS NR; HR, 7.80; 95% CI, 1.81-33.60). Similar results were observed in stage IV GC that the median progression-free survival (PFS, 4.0 VS 7.0 months; HR, 2.74; 95% CI, 1.58-4.78) and OS (12.0 VS 16.0 months; HR, 3.14; 95% CI, 1.67-5.92) was shorter in patients with top 50% mSFRP2. During the dynamic monitor along treatment, elevated mSFPR2 was associated with worse PFS (5.0 VS 7.0 months; HR, 2.17; 95% CI, 1.25-3.76) and OS (12.0 VS 15.5 months; HR, 3.51; 95% CI, 1.94-6.35) in stage IV patients. Conclusions: Our study shows the association between SFRP2 methylation and its dynamic change and prognosis in patients with gastric cancer. Our results provide a potential biomarker in ctDNA for prognosis and dynamic monitoring in patients with gastric cancer.

Published
2020

23. siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells.

Author

Liu W, Zhu F, Jiang Y, Sun D, Yang B, and Yan H

Subjects
Antineoplastic Agents pharmacology, Carcinoma, Hepatocellular, Caspase 3 metabolism, Cell Survival drug effects, Cisplatin pharmacology, Drug Resistance, Neoplasm, Gene Knockdown Techniques, Hep G2 Cells, Humans, Inhibitor of Apoptosis Proteins metabolism, Liver Neoplasms, RNA Interference, Survivin, Cell Proliferation, Inhibitor of Apoptosis Proteins genetics, RNA, Small Interfering genetics
Abstract

Survivin has become an attractive anticancer therapeutic target due to its important role in tumor cell viability and its selective expression in tumor cells. In the present study, we constructed a recombinant siRNA plasmid vector against survivin and stably transfected it into HepG2 and SMMC‑7721 hepatocellular carcinoma cells in vitro. Semi-quantitative RT-PCR and western blotting were used to determine the expression of survivin mRNA and protein, respectively. Tumor cell proliferation was assessed by trypan blue exclusion. We evaluated the change in caspase-3 activity, and the rate of cell apoptosis and the cell cycle distribution were analyzed by flow cytometry. Assessment of chemosensitivity was carried out by MTT assay. The results showed that transfection of survivin siRNA caused a significant inhibition of survivin mRNA and protein expression which was associated with cell growth inhibition, specific G0/G1 phase arrest, increased caspase-3 activity and enhanced chemosensitivity to cisplatin in both HCC cell lines. We suggest that suppression of survivin expression by RNAi attenuates the malignant phenotype of hepatocellular carcinoma cells, and may provide a novel approach for anticancer gene therapy.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results